How Lung Cancer Uses Its Own Peptide Signals to Fuel Growth | Research

The takeaway

Small cell lung cancer cells have high-affinity receptors for the peptide bombesin/GRP and produce these peptides themselves, creating a self-stimulating growth loop that could be targeted for treatment.

2,000 receptors per cancer cell
Each small cell lung cancer cell expresses about 2,000 high-affinity bombesin/GRP receptors, creating a self-stimulating peptide growth loop that fuels tumor expansion

What the researchers found

Human small cell lung cancer (SCLC) cells express high-affinity receptors for bombesin/GRP (gastrin-releasing peptide) — with about 2,000 binding sites per cell and a binding affinity (Kd) of 0.5 nM. The receptor binding was specific: bombesin and the structurally related peptide GRP competed for binding, but unrelated peptides like substance P and vasopressin did not.

Critically, since SCLC cells both produce bombesin/GRP-like peptides AND express receptors for them, these peptides likely function as autocrine growth factors — the cancer cells stimulate their own growth through a self-reinforcing peptide signaling loop. The receptor was identified as a 78,000-dalton (78 kDa) polypeptide.

Why it matters

This foundational study established that bombesin/GRP acts as an autocrine growth signal in small cell lung cancer — meaning the tumor stimulates its own growth through peptide signaling. This discovery opened an entirely new therapeutic approach: blocking the bombesin/GRP receptor to cut off the tumor's self-stimulation. It also made bombesin receptors a target for peptide-based cancer diagnostics and drug delivery, a concept that has since expanded to multiple cancer types.

The numbers in context

Kd = 0.5 nM binding affinity · ~2,000 receptors per cell · 78 kDa receptor protein · Specific for bombesin/GRP (not substance P or vasopressin) · Binding reversible and saturable

How the study worked

Researchers used radiolabeled bombesin analog ((125I-Tyr4)bombesin) to characterize receptor binding on two SCLC cell lines (NCI-H446 and NCI-H345). Binding kinetics, specificity, and competition with related and unrelated peptides were determined. The receptor protein was identified by affinity purification using bombesin and GRP resins, followed by SDS-PAGE gel electrophoresis.

Who was studied

In vitro study using human small cell lung cancer cell lines (NCI-H446 and NCI-H345)

What this study cannot tell us

This is an in vitro study using cultured cell lines, which may not fully represent the receptor expression and signaling dynamics of tumors in living patients. Only two SCLC cell lines were characterized. The autocrine growth hypothesis, while strongly supported by the data, was not directly tested with growth inhibition experiments in this paper. The study predates modern receptor cloning and molecular biology techniques.

How to read the evidence

This is a foundational in vitro study that characterized receptor binding with rigorous pharmacological methodology. While limited to cell lines, the findings have been extensively validated and expanded upon in subsequent decades of research. The autocrine signaling concept became a cornerstone of cancer peptide biology.

When this study was published

Published in 1985, this is a seminal study that established bombesin/GRP receptor biology in lung cancer. While the specific techniques are dated, the fundamental discovery has been validated thousands of times and underlies modern peptide receptor-targeted cancer therapies.

The bigger picture

This 1985 study was a landmark in cancer biology that established peptide receptor-mediated autocrine signaling as a driver of tumor growth. The concept that tumors use peptide receptors to fuel their own expansion has since been applied across many cancer types and led to the development of peptide receptor-targeted therapies — including radiolabeled peptide analogs for cancer imaging (PET scanning) and treatment (peptide receptor radionuclide therapy), as well as peptide-drug conjugates.

Questions still open

Have bombesin/GRP receptor antagonists been successfully developed as cancer therapeutics targeting the autocrine growth loop?
Can bombesin receptor expression be used as a biomarker to select SCLC patients for peptide-targeted therapies?
Do bombesin receptor levels on tumor cells correlate with disease aggressiveness or treatment response?

Common questions

What is autocrine signaling and why does it matter in cancer?

Autocrine signaling means a cell produces a chemical signal and also responds to it — essentially talking to itself. In this study, lung cancer cells produce the peptide bombesin/GRP AND have receptors for it, creating a self-stimulating growth loop. This matters because it means the cancer doesn't need signals from surrounding tissue to grow — it generates its own growth commands. Blocking this loop with drugs is now a major cancer treatment strategy.

How is this discovery used in cancer treatment today?

Bombesin/GRP receptors are now used as targets for both cancer detection and treatment. Radiolabeled bombesin analogs can be injected into patients to light up tumors on PET scans (diagnostic imaging). Similar peptide analogs carrying radioactive or toxic payloads can be used for targeted therapy — the peptide homes in on the cancer receptor and delivers its payload directly to the tumor, sparing healthy tissue.

Read the original research

High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer.

Life sciences, 37(2), 105-13

View on PubMed ↗

Citation

Moody, T W; Carney, D N; Cuttitta, F; Quattrocchi, K; Minna, J D. (1985). High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer.. Life sciences, 37(2), 105-13.